Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000953538
Ethics application status
Approved
Date submitted
26/06/2024
Date registered
6/08/2024
Date last updated
6/08/2024
Date data sharing statement initially provided
6/08/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Whole body 360 Degree, 3-Dimensional skin imaging to document change in atopic dermatitis severity following treatment with dupilumab
Query!
Scientific title
Whole body 360 Degree, 3-Dimensional skin imaging to document change in atopic dermatitis severity following treatment with dupilumab in adult patients
Query!
Secondary ID [1]
312411
0
RS-SNFDPL-2021-10-22
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Atopic Dermatitis
334222
0
Query!
Condition category
Condition code
Skin
330892
330892
0
0
Query!
Dermatological conditions
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
This study will enroll 15 male and female patients, aged 18 years and above, who are diagnosed with moderate to severe chronic AD and who are candidates for systemic therapy or phototherapy. The decision to prescribe Dupilumab will be made by the treating doctor independently. Participation in the study primarily involves consenting to full-body photography and completion of the DLQI questionnaire. Treatment of patients will follow the Australian prescribing label.
Dupilumab (300mg/ml)
Trade name: Dupixent
Dupilumab is an interleukin-4 (IL-4) receptor alpha antagonist. It is a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits IL-4 and interleukin-13 (IL-13) signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the type 1 receptor and both IL-4 and IL-13 signaling via the type 2 receptor. By blocking the IL-4R alpha subunit, Dupilumab inhibits IL-4 and IL-13 cytokine-induced responses, including the release of proinflammatory cytokines, chemokines, and immunoglobulin E alleviating AP symptoms.
This is an open-label, single-centre observational study looking at the photographic resolution of atopic dermatitis in patients receiving Dupilumab per standard regimen. 15 patients with moderate-to-severe chronic AD will be recruited. The decision to prescribe Dupilumab is made by the treating physician, prior to offering participation in this trial. Affected areas will be photographically mapped with whole body 3-D photography using Canfield Vectra WB360. Patients will take part for a maximum of 52 weeks in this study. The initial screening period is up to 4 weeks followed by scheduled visits at Baseline up to Week 52.
The study assessments include; Collecting patient demographics (date of birth, gender, ethnicity and child-bearing potential), Medical history, Concomitant treatment, physical examination, vital signs, whole-body photography, Eczema Area Severity Index, and Dermatology Life Quality Index.
All participants will be screened prior to enrolment in the study. The Baseline visit will occur no later than 28 days from Screening visit. Visits 3-10 must occur within 3 days from the scheduled dates based on the Baseline visit. Visits 11-14 must occur within 7 days from the scheduled dates based on the Baseline visit. For the end of study visit, a 7-day window applies based on the Baseline visit.
The decision to prescribe Dupilumab is made independently by the treating physician based on the patient's clinical needs, prior to any consideration of participation in this trial. Participants in this study will receive Dupilumab treatment irrespective of their involvement in the trial, and their decision to participate, discontinue participation, or discontinue Dupilumab treatment will not impact their access to standard medical care, including Dupilumab.
Enrollment in this observational study does not determine whether the participants receive Dupilumab; rather, it allows researchers to observe and collect data on the outcomes of Dupilumab treatment in a real-world setting. Therefore, participants would receive Dupilumab regardless of their involvement in the study, as it is prescribed independently of the study protocol and based solely on their medical requirements.
Query!
Intervention code [1]
328913
0
Not applicable
Query!
Comparator / control treatment
No control group.
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
338649
0
To document the incremental change in atopic dermatitis severity
Query!
Assessment method [1]
338649
0
Assessed through photographic analysis and using EASI (Eczema Area and Severity Index) scoring from Baseline to Week 52
Query!
Timepoint [1]
338649
0
Change in EASI scores will be assessed at every fortnightly visit from baseline to week 16, and then monthly from week 16 to week 52.
Query!
Primary outcome [2]
338728
0
To elucidate the pattern of resolution following treatment commencement with Dupilumab
Query!
Assessment method [2]
338728
0
Assess the resolution in atopic dermatitis severity through photographic analysis with the Canfield Vectra WB360 whole body surface imaging system and EASI (Eczema Area and Severity Index) score from Baseline to Week 52.
The photographic analyses and EASI scores will be assessed together.
Query!
Timepoint [2]
338728
0
The level of resolution will be assessed at every fortnightly visit from baseline to week 16, and then monthly from week 16 to week 52 by the investigator following image capture on the Canfield Vectra WB360.
Query!
Secondary outcome [1]
436838
0
To determine the impact of treatment with Dupilumab on quality of life
Query!
Assessment method [1]
436838
0
Change in DLQI (Dermatology Life Quality Index) score
Query!
Timepoint [1]
436838
0
DLQI will be completed by participants at every fortnightly visit from baseline to week 16, and then monthly from week 16 to week 52.
Query!
Eligibility
Key inclusion criteria
Participants eligible for inclusion in the study must fulfil all the following criteria:
1. Male or female at least 18 years of age at time of screening.
2. Diagnosis of chronic atopic dermatitis for at least 6 months at Baseline.
3. Active atopic dermatitis present for at least 6 months from initial diagnosis
4. Ability to comprehend and willing to sign and date an informed consent form (ICF).
5. Adults who are eligible for systemic therapy or phototherapy.
6. Qualify for PBS-reimbursed Dupilumab. Moderate to severe atopic dermatitis as defined at study enrolment by:
i. PGA is equal to 4
ii. EASI score is greater than or equal to 20
iii. Documented inadequate response to topical corticosteroids or systemic immunosuppressants
7. The most recent documented EASI assessment must be no more than one month old at the time of starting the first dose of dupilumab
8. Naïve to biologics therapy for the treatment of chronic atopic dermatitis
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Participants fulfilling any of these criteria are not eligible for inclusion in this study:
1. Current treatment with systemic JAK inhibitor
2. Use of investigational treatments within 4 weeks before study assignment, or within a period of 5 half-lives of the investigational treatment, whichever is longer.
3. Previous exposure to other biologics agents such as but not limited to secukinumab, ustekinumab, brodalumab, ixikizumab, adalimumab, infliximab, briakinumab, efalizumab, golimumab, etanercept, tildrakizumab, apremilast, guselkumab and tofacitinib.
4. Diagnosis of other forms of inflammatory skin conditions eg psoriasis, lymphatic disease (EBV Virus), HIV, Hepatitis, Hep C, Shingles (disseminated), immunodeficiency disorders, malignancies, Tuberculosis, Thrombocytopenia, coagulopathy or platelet dysfunction.
5. Underlying health conditions (including but not limited to metabolic, cardiac, endocrine, neurologic, infectious and hepatic) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy.
6. History of infections within the last 6 months requiring hospitalization.
7. Pregnant or lactating women; Lactating (nursing) women will need to cease prior to commencing dupilumab. This will need to be discussed with the treating physician and/or the appropriate healthcare professional.
8. Receiving anti-coagulants.
9. Received a live or attenuated vaccine within 6 weeks of day 1 visit.
10. Recently undergone surgery or significant trauma.
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
16/08/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
1/07/2025
Query!
Actual
Query!
Date of last data collection
Anticipated
1/07/2026
Query!
Actual
Query!
Sample size
Target
15
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Funding & Sponsors
Funding source category [1]
316822
0
Self funded/Unfunded
Query!
Name [1]
316822
0
Dr Rodney Sinclair Pty Ltd
Query!
Address [1]
316822
0
Query!
Country [1]
316822
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Dr Rodney Sinclair Pty Ltd
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
319053
0
None
Query!
Name [1]
319053
0
Query!
Address [1]
319053
0
Query!
Country [1]
319053
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
315592
0
Bellberry Human Research Ethics Committee K
Query!
Ethics committee address [1]
315592
0
https://bellberry.com.au/
Query!
Ethics committee country [1]
315592
0
Australia
Query!
Date submitted for ethics approval [1]
315592
0
15/04/2024
Query!
Approval date [1]
315592
0
11/07/2024
Query!
Ethics approval number [1]
315592
0
Query!
Summary
Brief summary
This is an open-label, single-centre observational study looking at the photographic resolution of atopic dermatitis in patients receiving Dupilumab per standard regimen. Patients will be photographed fortnightly from baseline to week 16, and then monthly from week 16 to week 52. 15 patients with moderate-to-severe chronic Atopic Dermatitis will be recruited. The decision to prescribe Dupilumab is made by the treating physician, prior to offering participation in this trial. Affected areas will be photographically mapped with whole body 3-D photography using Canfield Vectra WB360. Patients will take part for a maximum of 52 weeks in this study. The initial screening period is up to 4 weeks followed by scheduled visits at Week 0 (Baseline) and fortnightly visits up to Week 52. It is hypothesized that treatment with Dupilumab will lead to a statistically significant improvement in atopic dermatitis severity, as measured by the Eczema Area and Severity Index (EASI), and will correlate positively with improvements in quality of life, as assessed by the Dermatology Life Quality Index (DLQI), over the course of 52 weeks
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
135174
0
Prof Rodney Sinclair
Query!
Address
135174
0
Dr Rodney Sinclair Pty Ltd: Level 3, 2 Wellington Parade East Melbourne, VIC 3002
Query!
Country
135174
0
Australia
Query!
Phone
135174
0
+61 3 9013 0099
Query!
Fax
135174
0
Query!
Email
135174
0
[email protected]
Query!
Contact person for public queries
Name
135175
0
Laita Bokhari
Query!
Address
135175
0
Dr Rodney Sinclair Pty Ltd: Level 3, 2 Wellington Parade East Melbourne, VIC 3002
Query!
Country
135175
0
Australia
Query!
Phone
135175
0
+61 3 9013 0099
Query!
Fax
135175
0
Query!
Email
135175
0
[email protected]
Query!
Contact person for scientific queries
Name
135176
0
Laita Bokhari
Query!
Address
135176
0
Dr Rodney Sinclair Pty Ltd: Level 3, 2 Wellington Parade East Melbourne, VIC 3002
Query!
Country
135176
0
Australia
Query!
Phone
135176
0
+61 3 9013 0099
Query!
Fax
135176
0
Query!
Email
135176
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF